Dr Jonas Bergh honoured with the first ESMO Breast Cancer Award

Intro text: 

Professor Jonas Bergh, BIG official representative for the Swedish Breast Cancer Group (SweBCG), has been awarded with the first ESMO Breast Cancer Award. This award acknowledges dedication and contributions to research, development of education and change in clinical practice in the field of breast cancer.  

Dr Bergh’s work mainly focuses on the biology of breast cancer and his research has contributed to progress in many aspects of cancer epidemiology, prevention and treatment. He has been involved in showing the additional value of other drugs, notably chemotherapy, in breast cancer treatment.

An important trial by SweBCG, which was the first randomised study that showed that five years of tamoxifen treatment is better than the initially suggested two years of treatment. 


Dr Bergh is Co-Chair of the  Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), whose publications have had a global impact on primary breast cancer treatment, and was Chair of the Swedish Breast Cancer Group (SweBCG) between 1995 and 2016.

Dr Jonas Bergh is Cancer Theme Prefect and Director of Strategic Research Programme in Cancer at the Karolinska Institutet in Stockholm, Sweden, where he is also member of the Nobel Assembly and holds the Mimi Althainz' Professorship in Oncology. Bergh is also Senior Consultant in Oncology at the Karolinska University Hospital, Acting Chair of the Scientific Council in Oncology/Haematology for the European Medicines Agency (EMA), Visiting Professor of Breast Cancer Research at Oxford University, and a fellow of the Royal College of Physicians in London, UK.

Source: European Society for Medical Oncology (ESMO)


BIG trials at ESMO Breast 2019


AURORA (BIG 14-01): 1520 - Frist report of AURORA, the Breast International Group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients.
On 2 May 2019, the first report of the AURORA programme will be presented during a proffered paper session by Dr Philippe Aftimos, co- investigator of the programme. 

AURORA is an international, academic research programme that uses molecular screening technology to decode the genetic characteristics of a tumour and identify the changes (genetic aberrations) that drive disease evolution over time, in patients with recurrent or locally relapsed metastatic breast cancer.

ALTTO (BIG 2-06): 1990 – Long-term cardiac outcomes of HER2+ breast cancer patients treated in ALTTO trial.
Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial will be presented during a mini oral session on 4 May 2019 by Dr Daniel Eiger.

The ALTTO study investigated whether combining trastuzumab with lapatinib – given either alone, together or one after the other – benefits patients with human epidermal growth factor receptor 2 (HER2)-positive early breast. It also assessed the safety of lapatinib and aims to identify specific molecular markers to predict which patients will benefit most from lapatinib or trastuzumab.